PPD has signed a data-minded deal with the collection experts at ERT, a partnership the companies believe will help their clients conduct more efficient trials.
Infraredx is collaborating with Massachusetts General Hospital and its coronary imaging researcher Dr. Gary Tearney in a bid to further research and develop combination technologies that provide information about patients' coronary disease.
Ortho-Clinical Diagnostics rolled out Astute Medical's test for acute kidney injury in U.S. hospitals, chalking up a milestone in the companies' push to commercialize the product.
Ortho-Clinical Diagnostics announced that the NephroCheck diagnostic test for acute kidney injury is now available nationwide to hospitals, marking another step forward for the product that put developer Astute Medical among this year's Fierce 15 med tech companies.
Dialysis magnate Fresenius Medical Care, a leading provider of hemodialysis machines, has entered into a partnership to help commercialize the cytokine absorber CytoSorb to combat sepsis and other infections that can lead to organ failure. The financial terms of the pact were not disclosed.
Patrick Soon-Shiong, billionaire physician and biotech entrepreneur, wants in on the hottest field in oncology, forming a joint venture with Sorrento Therapeutics to develop therapies that harness the body's immune system to fight cancer.
Pfizer's business development team is on a spending spree. Today the pharma giant said it is partnering with Miami-based Opko Health on a Phase III long acting growth hormone, paying $295 million upfront and promising up to $275 million more on regulatory milestones.
X-Chem, PPD's in-house biotech company, has signed a deal with the rare disease specialists at Alexion to lend out its molecular library and help discover new treatments.
Developer and supplier of drug delivery systems Unilife announced last week the signing of a worldwide, 10-year commercial supply agreement with a global pharmaceutical company for the use of its Depot-ject with an ocular injection therapy.
Australian regenerative medicine company Orthocell and Scandinavian med tech BoneSupport will work together to combine their existing products into a new bone repair product. The pair hopes to further tap into the global bone graft and substitutes market, which the companies said was $2.1 billion last year and is expected to be $2.7 billion by 2020.